STOCK TITAN

BioAtla (BCAB) 424B Filings

BCAB OTC

Here are the 424B prospectus supplements from BioAtla Inc (BCAB) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 424B covers the supplement that carries the terms of a priced offering, so if you follow BCAB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BCAB filings page.

Rhea-AI Summary

BioAtla, Inc. registered up to 8,182,110 common shares for resale by YA II PN, Ltd.: up to 8,000,000 Advance Shares it may elect to issue and sell under the Standby Equity Purchase Agreement, plus 182,110 shares issuable upon exercise of Commitment Fee Warrants. BioAtla receives no proceeds from resales, but may receive up to $40,000,000 in gross proceeds from elected Advance Share sales during the 36 months after October 15, 2026.

Yorkville pays 97% of the lowest daily VWAP during the three trading days beginning with an advance notice, excluding Excluded Days; purchases are subject to a 4.99% beneficial-ownership cap. BioAtla had 1,668,261 shares outstanding as of October 16, 2026; all registered shares issued then would equal approximately 490.5% of that count.

BioAtla is exploring asset sales, licensing, partnerships and other strategic transactions, with no assurance of an agreement; restructuring included a workforce reduction of approximately 70%. Further enrollment in Phase 1 BA3182 was paused, while treatment and follow-up continued. Cash and cash equivalents were approximately $1.5 million as of June 30, 2026; BioAtla said these resources were insufficient to fund ongoing operations for at least 12 months from issuance of the financial statements, raising substantial doubt about its ability to continue as a going concern.

Rhea-AI Summary

BioAtla is registering 842,440 shares of common stock to be issued to YA II PN, Ltd. pursuant to its Standby Equity Purchase Agreement dated November 20, 2025. The shares are priced at approximately $0.179 per share for total proceeds of approximately $151,000, which the company intends to use for working capital and general corporate purposes. The company expects to issue the shares on or about March 20, 2026. This prospectus supplement also covers the resale of these shares by YA II PN, Ltd. to the public.

Common stock outstanding after the offering will be 82,846,317 shares. The resale and methods of sale are described in the referenced "Plan of Distribution."

Rhea-AI Summary

BioAtla is offering 631,163 shares of common stock to YA II PN, Ltd. (Yorkville) at approximately $0.171 per share pursuant to a Standby Equity Purchase Agreement dated November 20, 2025. The total purchase price is approximately $108,000 and the company expects to issue the shares on or about March 13, 2026. This prospectus supplement also covers the resale of those shares by Yorkville to the public. Common stock outstanding after the issuance will be 81,801,593 shares. The company states it intends to use net proceeds for working capital and other general corporate purposes.

Rhea-AI Summary

BioAtla is issuing 931,032 shares of common stock to YA II PN, Ltd. under a Standby Equity Purchase Agreement dated November 20, 2025, at approximately $0.166 per share for total gross proceeds of approximately $154,000. The company expects to issue the shares on or about March 9, 2026.

The prospectus supplement also covers the resale of these shares by YA II PN, Ltd. to the public. Common stock outstanding after the issuance would be 81,170,430 shares.